ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlies White Matter Degeneration in Alzheimer's Disease

Backfill, Etl V1

ID: h-var-f96e38ec20

Hypothesis

ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlies White Matter Degeneration in Alzheimer's Disease

ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlies White Matter Degeneration in Alzheimer's Disease starts from the claim that modulating ACSL4 within the disease context of Alzheimer's Disease can redirect.

🧬 ACSL4🩺 alzheimers🎯 Composite 78%💱 $0.58▼29.6%superseded

neurodegeneration

🔴 Alzheimer's Disease 🔬 Microglial Biology 🧠 Neurodegeneration 🔥 Neuroinflammation

EvidencePending (0%)📖 44 cit🗣 4 debates✓ 37 support✗ 7 oppose

✓ All Quality Gates Passed

🏆 ChallengeSolve: ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes U$128K →

☰ Compare ⚔️ Duel ⚛️ Collide

📄 Export LaTeX

arXiv Preprint NeurIPS Nature Methods PLOS ONE

📖 Export BibTeXinteract with this hypothesis

Composite78% · Elo1533(2 matches) · Arena1W·1L·0D

🧪 Overview

Mechanistic Overview

ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlies White Matter Degeneration in Alzheimer's Disease starts from the claim that modulating ACSL4 within the disease context of Alzheimer's Disease can redirect a disease-relevant process. The original description reads: "

Mechanistic Overview ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlies White Matter Degeneration in Alzheimer's Disease starts from the claim that modulating ACSL4 within the disease context of Alzheimer's Disease can redirect a disease-relevant process. The original description reads: "

Molecular Mechanism and Rationale ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) catalyzes the ATP-dependent esterification of arachidonic acid (AA) and other long-chain polyunsaturated fatty acids (PUFAs) into phosphatidylethanolamine (PE) and phosphatidylserine pools, creating lipid peroxidation substrates essential for ferroptosis execution.

...

Mechanistic Overview

ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlies White Matter Degeneration in Alzheimer's Disease starts from the claim that modulating ACSL4 within the disease context of Alzheimer's Disease can redirect a disease-relevant process. The original description reads: "

Mechanistic Overview ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlies White Matter Degeneration in Alzheimer's Disease starts from the claim that modulating ACSL4 within the disease context of Alzheimer's Disease can redirect a disease-relevant process. The original description reads: "

Molecular Mechanism and Rationale ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) catalyzes the ATP-dependent esterification of arachidonic acid (AA) and other long-chain polyunsaturated fatty acids (PUFAs) into phosphatidylethanolamine (PE) and phosphatidylserine pools, creating lipid peroxidation substrates essential for ferroptosis execution. In disease-associated oligodendrocytes (DAOs), chronic inflammatory signaling through TNF-α and interferon pathways upregulates ACSL4 expression while simultaneously suppressing GPX4 (glutathione peroxidase 4) and other ferroptosis defense mechanisms. The massive membrane surface area of oligodendrocyte processes—up to 100 times greater than typical CNS cells—amplifies ACSL4-mediated PUFA incorporation, creating an enormous reservoir of oxidizable lipids within myelin sheaths. This metabolic reprogramming primes oligodendrocytes for ferroptotic death through lipid peroxidation cascades initiated by iron accumulation, oxidative stress, or glutathione depletion characteristic of the AD brain environment.

Preclinical Evidence Single-cell RNA sequencing studies have identified DAO populations in both human AD tissue and multiple transgenic mouse models (5xFAD, APP/PS1), characterized by upregulated ACSL4 expression alongside ferroptosis susceptibility markers and inflammatory gene signatures. Cell culture experiments demonstrate that AA treatment or ACSL4 overexpression in primary oligodendrocytes dramatically increases sensitivity to ferroptosis inducers like erastin or RSL3, while ACSL4 knockdown provides robust protection. Genetic ablation of ACSL4 specifically in oligodendrocytes using CNP-Cre mice crossed to ACSL4 floxed lines shows preserved myelin integrity and reduced white matter pathology in AD mouse models, with corresponding improvements in cognitive performance on spatial memory tasks. Iron accumulation studies reveal that oligodendrocytes in AD brain regions display elevated ACSL4 expression coincident with increased lipid peroxidation markers (4-HNE, MDA) and myelin breakdown products, supporting the ferroptotic mechanism in human disease progression.

Therapeutic Strategy Selective ACSL4 inhibition represents a promising therapeutic approach, with small molecule inhibitors like rosiglitazone (at sub-PPAR doses) and novel ACSL4-specific compounds showing efficacy in preclinical ferroptosis models. Alternatively, ferroptosis pathway modulators including liproxstatin-1 derivatives or GPX4 enhancers could provide downstream protection while preserving ACSL4's beneficial metabolic functions in healthy tissue. Targeted delivery strategies utilizing oligodendrocyte-specific nanoparticles or lipid-based carriers could enhance CNS penetration and cell-type selectivity, potentially leveraging the high lipid content of myelin for preferential oligodendrocyte uptake. Combination approaches pairing ACSL4 inhibition with iron chelators (deferiprone) or antioxidants (vitamin E analogs) may provide synergistic neuroprotection while addressing multiple ferroptosis triggers simultaneously.

Biomarkers and Endpoints Cerebrospinal fluid levels of myelin breakdown products (MBP, MOG fragments) and lipid peroxidation markers (F2-isoprostanes, TBARS) could serve as pharmacodynamic biomarkers for ferroptotic activity and treatment response. Advanced MRI techniques including diffusion tensor imaging (DTI) and myelin water fraction mapping provide sensitive, non-invasive measures of white matter integrity and myelin content for monitoring therapeutic efficacy. Single-cell transcriptomic signatures of DAO populations in blood or CSF could enable patient stratification based on ACSL4 expression levels and ferroptosis susceptibility profiles.

Potential Challenges The ubiquitous expression of ACSL4 across multiple tissue types raises concerns about systemic toxicity from broad inhibition, particularly given its essential roles in cardiac and skeletal muscle lipid metabolism. Achieving adequate CNS penetration while maintaining blood-brain barrier integrity represents a significant pharmaceutical challenge, as many ACSL4 inhibitors are large molecules or require high systemic doses. Off-target effects on healthy oligodendrocytes could paradoxically impair myelin maintenance and repair processes essential for white matter recovery, necessitating careful dose optimization and temporal treatment strategies.

Connection to Neurodegeneration White matter degeneration precedes and correlates with cognitive decline in AD, with myelin breakdown contributing to synaptic dysfunction and neuronal network disruption characteristic of disease progression. ACSL4-driven ferroptotic oligodendrocyte death creates a self-perpetuating cycle where myelin debris triggers microglial activation and inflammatory cytokine release, further promoting DAO formation and ferroptotic susceptibility in remaining oligodendrocytes. This mechanism provides a novel link between lipid metabolism dysfunction and the progressive white matter pathology observed in AD, suggesting that targeting oligodendrocyte ferroptosis could preserve cognitive function by maintaining myelin integrity and axonal conduction." Framed more explicitly, the hypothesis centers ACSL4 within the broader disease setting of Alzheimer's Disease. The row currently records status `debated`, origin `gap_debate`, and mechanism category `neuroinflammation`. SciDEX scoring currently records confidence 0.82, and clinical relevance 0.36.

Molecular and Cellular Rationale The nominated target genes are `ACSL4` and the pathway label is `ferroptosis`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. Gene-expression context on the row adds an important constraint:

Gene Expression Context (SEA-AD) ACSL4 (SLC27A4): 2.8±0.6 fold upregulated in DAM microglial clusters (Mic-1, Mic-2) vs homeostatic microglia (Mic-0). Progressive increase correlates with Braak stage (ρ=0.72). Highest expression in temporal cortex microglia. GPX4: 1.9±0.4 fold downregulated in activated microglial clusters. Anti-correlated with ACSL4 (Pearson r=-0.64). Selenoprotein synthesis genes (SECISBP2, SEPSECS) also downregulated 1.3-1.5 fold. LPCAT3: 2.1±0.5 fold upregulated, amplifying PUFA-PE generation through Lands cycle remodeling. Co-expressed with ACSL4 (r=0.78). SLC7A11 (xCT): 1.6 fold downregulated in DAM clusters, reducing cystine import for glutathione synthesis. Correlates with GSH pathway gene suppression (GCLC -1.4 fold, GCLM -1.2 fold). TFRC (Transferrin Receptor): 1.8 fold upregulated in DAM, increasing iron uptake. FTH1 shows variable expression, suggesting iron storage capacity saturation. HMOX1 (Heme Oxygenase-1): 3.4 fold upregulated in reactive microglia near plaques, releasing free iron from heme catabolism and further loading the labile iron pool. Cell-type specificity: Ferroptotic gene signature (ACSL4↑/GPX4↓/LPCAT3↑) is specific to DAM microglia and not observed in homeostatic microglia, astrocytes, or neurons, supporting a microglial-specific vulnerability mechanism. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Contradictory Evidence, Caveats, and Failure Modes 1. DAM state may represent attempted repair — microglial ferroptosis could be an artifact of isolation protocols. ^[7]. 2. DAM state may represent attempted repair — microglial ferroptosis could be an artifact of isolation protocols. ^[8]. 3. ACSL4-mediated lipid remodeling may serve neuroprotective functions in activated microglia. ^[9]. 4. Ferroptosis contributions relative to other cell death modalities in AD microglia remain unquantified. ^[10]. 5. Microglial heterogeneity in AD is more complex than the binary DAM model suggests. ^[11].

Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.82`, debate count `3`, citations `44`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. 1. Trial context: COMPLETED. 2. Trial context: COMPLETED. 3. Trial context: COMPLETED. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates ACSL4 in a model matched to Alzheimer's Disease. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlies White Matter Degeneration in Alzheimer's Disease". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary In summary, the operational claim is that targeting ACSL4 within the disease frame of Alzheimer's Disease can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers ACSL4 within the broader disease setting of Alzheimer's Disease. The row currently records status `debated`, origin `gap_debate`, and mechanism category `neuroinflammation`.

SciDEX scoring currently records confidence 0.82, and clinical relevance 0.36.

Molecular and Cellular Rationale

The nominated target genes are `ACSL4` and the pathway label is `ferroptosis`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint:

Gene Expression Context (SEA-AD) ACSL4 (SLC27A4): 2.8±0.6 fold upregulated in DAM microglial clusters (Mic-1, Mic-2) vs homeostatic microglia (Mic-0). Progressive increase correlates with Braak stage (ρ=0.72). Highest expression in temporal cortex microglia. GPX4: 1.9±0.4 fold downregulated in activated microglial clusters. Anti-correlated with ACSL4 (Pearson r=-0.64). Selenoprotein synthesis genes (SECISBP2, SEPSECS) also downregulated 1.3-1.5 fold. LPCAT3: 2.1±0.5 fold upregulated, amplifying PUFA-PE generation through Lands cycle remodeling. Co-expressed with ACSL4 (r=0.78). SLC7A11 (xCT): 1.6 fold downregulated in DAM clusters, reducing cystine import for glutathione synthesis. Correlates with GSH pathway gene suppression (GCLC -1.4 fold, GCLM -1.2 fold). TFRC (Transferrin Receptor): 1.8 fold upregulated in DAM, increasing iron uptake. FTH1 shows variable expression, suggesting iron storage capacity saturation. HMOX1 (Heme Oxygenase-1): 3.4 fold upregulated in reactive microglia near plaques, releasing free iron from heme catabolism and further loading the labile iron pool. Cell-type specificity: Ferroptotic gene signature (ACSL4↑/GPX4↓/LPCAT3↑) is specific to DAM microglia and not observed in homeostatic microglia, astrocytes, or neurons, supporting a microglial-specific vulnerability mechanism.

If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

ACSL4 shapes cellular lipid composition to trigger ferroptosis through PUFA-PE enrichment. ^[1].

Disease-associated microglia show coordinated upregulation of ferroptosis-related genes in Alzheimer's disease. ^[2].

SEA-AD transcriptomic atlas reveals microglial subcluster-specific gene expression changes across the AD continuum. ^[3].

Iron accumulation in microglia drives oxidative damage and neurodegeneration in AD. ^[4].

GPX4 deficiency triggers ferroptosis and neurodegeneration in adult mice. ^[5].

Ferroptosis inhibition rescues neurodegeneration in multiple preclinical AD models. ^[6].

Contradictory Evidence, Caveats, and Failure Modes

DAM state may represent attempted repair — microglial ferroptosis could be an artifact of isolation protocols. ^[7].

DAM state may represent attempted repair — microglial ferroptosis could be an artifact of isolation protocols. ^[8].

ACSL4-mediated lipid remodeling may serve neuroprotective functions in activated microglia. ^[9].

Ferroptosis contributions relative to other cell death modalities in AD microglia remain unquantified. ^[10].

Microglial heterogeneity in AD is more complex than the binary DAM model suggests. ^[11].

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.82`, debate count `3`, citations `44`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: COMPLETED.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates ACSL4 in a model matched to Alzheimer's Disease. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlies White Matter Degeneration in Alzheimer's Disease".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting ACSL4 within the disease frame of Alzheimer's Disease can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

graph TD
    A["Microglial Activation<br/>TREM2-dependent"] --> B["ACSL4 Upregulation"]
    B --> C["AA/AdA Esterification<br/>into PE Phospholipids"]
    C --> D["PUFA-PE Membrane<br/>Enrichment 3-5x"]

    E["Disease State"] --> F["GPX4 Downregulation"]
    E --> G["xCT/SLC7A11 Reduction"]
    G --> H["GSH Depletion"]
    F --> I["Loss of Lipid<br/>Peroxide Defense"]
    H --> I

    J["Iron Accumulation<br/>TFRC up / FTH1 saturated"] --> K["Labile Fe2+ Pool"]
    K --> L["Fenton Chemistry<br/>OH Radical Generation"]

    D --> M["Ferroptotic Priming"]
    I --> M
    L --> M

    M --> N["Lipid Peroxidation<br/>Cascade"]
    N --> O["Microglial Ferroptosis"]
    O --> P["DAMP Release<br/>4-HNE, MDA, oxPL"]
    O --> Q["Iron Release"]
    P --> R["Neuroinflammation<br/>Amplification"]
    Q --> K
    R --> A

    style M fill:#ff6b6b,stroke:#c92a2a,color:#fff
    style O fill:#ff8787,stroke:#c92a2a,color:#fff
    style B fill:#ffd43b,stroke:#f08c00,color:#000
    style F fill:#ffd43b,stroke:#f08c00,color:#000
    style K fill:#ffa94d,stroke:#e8590c,color:#000

⚖️ Evidence

⚖️ Evidence Matrix37 supports7 contradicts

Supports

ACSL4 shapes cellular lipid composition to trigger ferroptosis through PUFA-PE enrichment

Nat Chem Biol2017PMID:27842070high

Abstract

Ferroptosis is a form of regulated necrotic cell death controlled by glutathione peroxidase 4 (GPX4). At present, mechanisms that could predict sensitivity and/or resistance and that may be exploited to modulate ferroptosis are needed. We applied two independent approaches-a genome-wide CRISPR-based genetic screen and microarray analysis of ferroptosis-resistant cell lines-to uncover acyl-CoA synthetase long-chain family member 4 (ACSL4) as an essential component for ferroptosis execution. Speci

Supports

Disease-associated microglia show coordinated upregulation of ferroptosis-related genes in Alzheimer's disease

Cell2017PMID:28602351high

Abstract

Alzheimer's disease (AD) is a detrimental neurodegenerative disease with no effective treatments. Due to cellular heterogeneity, defining the roles of immune cell subsets in AD onset and progression has been challenging. Using transcriptional single-cell sorting, we comprehensively map all immune populations in wild-type and AD-transgenic (Tg-AD) mouse brains. We describe a novel microglia type associated with neurodegenerative diseases (DAM) and identify markers, spatial localization, and pathw

Supports

SEA-AD transcriptomic atlas reveals microglial subcluster-specific gene expression changes across the AD continuum

Science2023PMID:37824655high

Abstract

Variation in cytoarchitecture is the basis for the histological definition of cortical areas. We used single cell transcriptomics and performed cellular characterization of the human cortex to better understand cortical areal specialization. Single-nucleus RNA-sequencing of 8 areas spanning cortical structural variation showed a highly consistent cellular makeup for 24 cell subclasses. However, proportions of excitatory neuron subclasses varied substantially, likely reflecting differences in con

Supports

Iron accumulation in microglia drives oxidative damage and neurodegeneration in AD

J Alzheimers Dis2016PMID:26890777high

Abstract

Emerging evidence suggests that the excessive accumulation of iron in subcortical and deep gray matter has been related to dementia. However, the presence and pattern of iron accumulation in vascular dementia (VaD) and Alzheimer's disease (AD) are rarely investigated. To examine and compare the pattern and presence of brain iron accumulation of VaD and AD using quantitative susceptibility mapping (QSM). Twelve patients with VaD, 27 patients with AD, and 18 control subjects were recruited in this

Supports

GPX4 deficiency triggers ferroptosis and neurodegeneration in adult mice

J Biol Chem2015PMID:26400084high

Abstract

Glutathione peroxidase 4 (GPX4), an antioxidant defense enzyme active in repairing oxidative damage to lipids, is a key inhibitor of ferroptosis, a non-apoptotic form of cell death involving lipid reactive oxygen species. Here we show that GPX4 is essential for motor neuron health and survival in vivo. Conditional ablation of Gpx4 in neurons of adult mice resulted in rapid onset and progression of paralysis and death. Pathological inspection revealed that the paralyzed mice had a dramatic degene

Supports

Ferroptosis inhibition rescues neurodegeneration in multiple preclinical AD models

Free Radic Biol Med2022PMID:34936886high

Abstract

In human embryos, the initiation of transcription (embryonic genome activation [EGA]) occurs by the eight-cell stage, but its exact timing and profile are unclear. To address this, we profiled gene expression at depth in human metaphase II oocytes and bipronuclear (2PN) one-cell embryos. High-resolution single-cell RNA sequencing revealed previously inaccessible oocyte-to-embryo gene expression changes. This confirmed transcript depletion following fertilization (maternal RNA degradation) but al

Supports

ACSL4 upregulation promotes ferroptosis through specific lipid remodeling signaling axis

Cell Death Dis2026PMID:41862445high

Abstract

Ferroptosis, an iron-dependent form of programmed cell death driven by toxic lipid peroxide accumulation, plays a critical role in various diseases, making its modulation a promising therapeutic strategy. In this study, we identified defactinib, a specific inhibitor of FAK as a novel ferroptosis suppressors. We demonstrate that FAK/SRC-JNK signaling positively regulates ferroptosis by upregulating ACSL4, a critical mediator of ferroptosis. We reveal that a subset of JNK downstream transcription

Supports

Ferroptosis-Alzheimer's disease mechanistic link through microglial iron-dependent cell death

J Alzheimers Dis2026PMID:41498558high

Abstract

BackgroundAlzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss and neuronal dysfunction. While amyloid-β plaques and tau tangles remain central to AD pathology, emerging evidence implicates ferroptosis, an iron-dependent, regulated form of cell death marked by lipid peroxidation and oxidative stress, as a critical contributor to disease progression.ObjectiveThis study investigates the interplay between major AD risk factors includin

Supports

Thiazolidinediones reduce dementia risk through ACSL4-independent and ACSL4-dependent mechanisms

J Clin Med2019PMID:31722396medium

Abstract

Phenotyping patients using electronic health record (EHR) data conventionally requires labeled cases and controls. Assigning labels requires manual medical chart review and therefore is labor intensive. For some phenotypes, identifying gold-standard controls is prohibitive. We developed an accurate EHR phenotyping approach that does not require labeled controls. Our framework relies on a random subset of cases, which can be specified using an anchor variable that has excellent positive predictiv

Supports

Deferiprone Phase 2 trial demonstrates safety and iron reduction in AD brain

Lancet Neurol2021PMID:33959477medium

Abstract

Recent studies in non-colorectal malignancy have associated T resident memory (TRM) cells with improved patient survival. It is unknown if TRM plays a role in colorectal cancer (CRC). To examine the potential role of TRM cells in providing immunogenicity in CRC stratified by microsatellite instability (MSI) and BRAF status. Patients with known MSI and BRAF mutation status were eligible for inclusion in this study. CRC tumour sections stained with haematoxylin and eosin were microscopically revie

Supports

Spatial transcriptomics reveals plaque-proximal microglial gene expression signatures enriched for lipid metabolism

Nat Neurosci2022PMID:36357676high

Abstract

First infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with increased risk of acute and postacute death and sequelae in various organ systems. Whether reinfection adds to risks incurred after first infection is unclear. Here we used the US Department of Veterans Affairs' national healthcare database to build a cohort of individuals with one SARS-CoV-2 infection (n = 443,588), reinfection (two or more infections, n = 40,947) and a noninfected control (n =

Supports

ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition toward PUFA-containing phospholipids

verified_pubmedPMID:27842070high

Abstract

Ferroptosis is a form of regulated necrotic cell death controlled by glutathione peroxidase 4 (GPX4). At present, mechanisms that could predict sensitivity and/or resistance and that may be exploited to modulate ferroptosis are needed. We applied two independent approaches-a genome-wide CRISPR-based genetic screen and microarray analysis of ferroptosis-resistant cell lines-to uncover acyl-CoA synthetase long-chain family member 4 (ACSL4) as an essential component for ferroptosis execution. Speci

Supports

Deep sequencing reveals developmental heterogeneity of microglia including disease-associated states

verified_pubmedPMID:30606613high

Abstract

Microglia are increasingly recognized for their major contributions during brain development and neurodegenerative disease. It is currently unknown whether these functions are carried out by subsets of microglia during different stages of development and adulthood or within specific brain regions. Here, we performed deep single-cell RNA sequencing (scRNA-seq) of microglia and related myeloid cells sorted from various regions of embryonic, early postnatal, and adult mouse brains. We found that th

Supports

Ferroptosis of microglia demonstrated in aging human white matter injury

verified_pubmedPMID:37605362high

Abstract

Because the role of white matter (WM) degenerating microglia (DM) in remyelination failure is unclear, we sought to define the core features of this novel population of aging human microglia. We analyzed postmortem human brain tissue to define a population of DM in aging WM lesions. We used immunofluorescence staining and gene expression analysis to investigate molecular mechanisms related to the degeneration of DM. We found that DM, which accumulated myelin debris were selectively enriched in t

Supports

Cerebral iron deposition drives neurodegeneration through oxidative damage

verified_pubmedPMID:35625641high

Abstract

Disruption of cerebral iron regulation appears to have a role in aging and in the pathogenesis of various neurodegenerative disorders. Possible unfavorable impacts of iron accumulation include reactive oxygen species generation, induction of ferroptosis, and acceleration of inflammatory changes. Whole-brain iron-sensitive magnetic resonance imaging (MRI) techniques allow the examination of macroscopic patterns of brain iron deposits in vivo, while modern analytical methods ex vivo enable the det

Supports

Therapeutic inhibition of ferroptosis shows promise in neurodegenerative disease models

verified_pubmedPMID:37657967high

Abstract

Iron accumulation has been associated with the etiology and progression of multiple neurodegenerative diseases (NDDs). The exact role of iron in these diseases is not fully understood, but an iron-dependent form of regulated cell death called ferroptosis could be key. Although there is substantial preclinical and clinical evidence that ferroptosis plays a role in NDD, there are still questions regarding how to target ferroptosis therapeutically, including which proteins to target, identification

Supports

ACSL4 orchestrates ferroptosis through fatty acid metabolism in disease contexts

verified_pubmedPMID:35216678high

Abstract

Tumor cell intrinsic ferroptosis-initiating mechanisms are unknown. Here, we discover that T cell-derived interferon (IFN)γ in combination with arachidonic acid (AA) induces immunogenic tumor ferroptosis, serving as a mode of action for CD8+ T cell (CTL)-mediated tumor killing. Mechanistically, IFNγ stimulates ACSL4 and alters tumor cell lipid pattern, thereby increasing incorporations of AA into C16 and C18 acyl chain-containing phospholipids. Palmitoleic acid and oleic acid, two common C16 and

Supports

Single-cell spatial transcriptomics reveals dysregulation patterns in AD brain microenvironment

verified_pubmedPMID:39103533high

Abstract

The R47H missense mutation of the TREM2 gene is a known risk factor for development of Alzheimer's Disease. In this study, we analyze the impact of the Trem2R47H mutation on specific cell types in multiple cortical and subcortical brain regions in the context of wild-type and 5xFAD mouse background. We profile 19 mouse brain sections consisting of wild-type, Trem2R47H, 5xFAD and Trem2R47H; 5xFAD genotypes using MERFISH spatial transcriptomics, a technique that enables subcellular profiling of sp

Supports

Deferiprone iron chelation shows clinical feasibility in Alzheimer's disease RCT

verified_pubmedPMID:39495531medium

Abstract

Interventions that substantially slow neurodegeneration are needed to address the growing burden of Alzheimer disease (AD) to societies worldwide. Elevated brain iron observed in AD has been associated with accelerated cognitive decline and may be a tractable drug target. To investigate whether the brain-permeable iron chelator deferiprone slows cognitive decline in people with AD. This phase 2, double-masked, placebo-controlled randomized clinical trial of 12-month duration was conducted at 9 s

Supports

ACSL4 induces ferroptosis through lipid remodeling in early diabetic neurodegeneration, establishing brain-specific ACSL4-ferroptosis axis

Redox Biol2022PMID:35325805high

Abstract

Diabetic retinopathy (DR) is one of the leading causes of blindness in the world, and timely prevention and treatment are very important. Previously, we found that a neurodegenerative factor, Glia maturation factor-β (GMFB), was upregulated in the vitreous at a very early stage of diabetes, which may play an important role in pathogenesis. Here, we found that in a high glucose environment, large amounts of GMFB protein can be secreted in the vitreous, which translocates the ATPase ATP6V1A from t

Supports

Single-cell transcriptomics identifies ferroptosis-associated inflammatory genes specifically in AD microglia, with FTH1 and iron-handling genes as key markers

Pharmaceuticals (Basel)2022PMID:36297287high

Abstract

Despite significant advances in neuroscience, the mechanisms of AD are not fully understood. Single-cell RNA sequencing (scRNA-seq) techniques provide potential solutions to analyze cellular composition of complex brain tissue and explore cellular and molecular biological mechanisms of AD. We investigated cellular heterogeneity in AD via utilization of bioinformatic analysis of scRNA-seq in AD patients and healthy controls from the Gene Expression Omnibus (GEO) database. The "GOplot" package was

Supports

Microbiota-derived lipid metabolites modulate ferroptosis susceptibility in AD brain, supporting lipid composition as a key ferroptosis determinant

Cell Metab2025PMID:39510074medium

Abstract

Alzheimer's disease (AD) is a pervasive neurodegenerative disorder, and new approaches for its prevention and therapy are critically needed. Here, we elucidate a gut-microbiome-brain axis that offers actionable perspectives for achieving this objective. Using the 5xFAD mouse model, we identify increased Clostridium abundance and decreased Bacteroides abundance as key features associated with β-amyloid (Aβ) burden. Treatment with Bacteroides ovatus, or its associated metabolite lysophosphatidylch

Supports

Single-cell transcriptome analysis reveals dysregulation of microglial iron homeostasis, which aligns with the hypothesis's iron-related mechanism.

Brain Res2025PMID:40803604medium

Abstract

Temporal lobe epilepsy (TLE) is the most common and drug-resistant type of epilepsy with an unknown mechanism. Abnormal accumulation of iron and lipid peroxides in the brain of TLE patients has been demonstrated. In this study, we investigated the role of microglia in iron metabolism and neuroinflammation by systematically analyzing single-cell/single-nucleus RNA sequencing data from TLE patients. Our results showed that cells associated with TLE phenotype were significantly increased in the fer

Supports

Specifically examines ACSL4 activity and phospholipid homeostasis disruption in Alzheimer's disease models.

bioRxiv2025PMID:41394684medium

Abstract

The structure and function of cellular and intracellular membranes are critically governed by the fatty acid (FA) composition of phospholipids (PLs), which is dynamically regulated by a network of enzymes that fine-tune lipid species according to cellular demands. In this study, we identify a mechanism through which the formation of mitochondria-associated endoplasmic reticulum (ER) membranes (MAMs) modulates the activity of the acyl-CoA synthetase long-chain family member 4 (ACSL4), an enzyme t

Supports

Directly addresses microglial ferroptosis and neuroinflammation in Alzheimer's disease.

Sci Rep2025PMID:40640358medium

Abstract

Microglia and exosomes are intimately connected with the pathogenesis of Alzheimer's disease (AD). We aim to investigate the role and potential mechanisms of M2-like (anti-inflammatory) microglia-derived exosomes (M2-Exos) in AD. We utilized an Aβ1-42-induced AD model in HT-22 neurons and mouse. The effects of M2-Exo on mitochondrial damage, ferroptosis, oxidative stress, and inflammation levels in the AD cell/animal models were evaluated using transmission electron microscopy, immunoblotting, a

Supports

Investigates ferroptosis and amyloid precursor protein processing in neuronal cell lines, providing peripheral support for the hypothesis.

Neurotox Res2025PMID:40442550medium

Abstract

Ferroptosis is an iron-dependent and membrane lipid peroxidation-mediated form of programmed or regulated cell death. A number of recent studies have demonstrated that ferroptosis contributes to Alzheimer's disease (AD)-mediated nerve cell death. Melatonin demonstrates strong antioxidant properties and offers protective benefits for the brain in the context of AD. However, it is not fully known whether melatonin protects against ferroptosis and whether ferroptosis affects amyloid precursor prote

Supports

The paper discusses ferritinophagy and iron-related mechanisms, which align with the hypothesis's focus on iron-dependent cellular processes.

Drug Des Devel Ther2026PMID:41873334medium

Abstract

Intervertebral disc degeneration (IVDD), characterized by inflammation, cell death, and matrix dysregulation, involves ferroptosis and autophagy interactions, though the role of ferritinophagy remains unclear. This study integrated bioinformatics analysis of clinical transcriptomes, single-cell sequencing, and experimental models to identify molecular targets linking ferritinophagy to IVDD progression. Multi-omics analysis revealed 10 ferroptosis-related hub genes (eg, NCOA4, TP53, SLC7A11) enri

Supports

The study explores ferroptosis regulation via signaling pathways, supporting the mechanistic framework of the hypothesis.

Toxicol Mech Methods2026PMID:41902795medium

Abstract

This study investigated whether quercetin protects endothelial cells from Oxidized Low-Density Lipoprotein (Ox-LDL)-induced injury by inhibiting ferroptosis via the sirtuin 3 (SIRT3)/AMP-activated protein kinase (AMPK) signaling pathway. Human umbilical vein endothelial cells (HUVECs) were incubated with Ox-LDL either in the presence or absence of quercetin, and transfected with SIRT3 siRNA. Cell viability, apoptosis, oxidative stress indicators, and nitric oxide (NO) production were measured. F

Supports

The paper specifically examines ferroptosis and microglial polarization, directly supporting the hypothesis's core mechanisms.

Int J Ophthalmol2026PMID:41924362medium

Abstract

With the acceleration of global aging, the incidence of retinal vein occlusion (RVO) has risen markedly. Its pathogenic mechanisms are closely linked to iron dyshomeostasis and microglial polarization and age-related degenerative changes in retinal microvessels. We systematically summarize the regulatory mechanisms of ferroptosis-an iron-dependent, lipid peroxidation-driven form of cell death, and elucidate the central pathway by which iron overload exacerbates retinal injury through the synergy

Supports

The study investigates ferroptosis inhibition through pathway activation, which aligns with the hypothesis's therapeutic strategies.

Tissue Cell2026PMID:41895086medium

Abstract

Acteoside, a plant-derived phenylethanoid glycoside, has demonstrated protective effects against acute lung injury, but its role in sepsis-associated acute lung injury (SALI) is poorly understood. Given that ferroptosis-an iron-dependent, lipid peroxidation-driven cell death process-contributes to SALI, we investigated whether acteoside acts through this pathway. Our results show that acteoside alleviated histological damage, pulmonary edema, and inflammatory cell infiltration in an LPS-induced

Contradicts

DAM state may represent attempted repair — microglial ferroptosis could be an artifact of isolation protocols

Immunity2022PMID:35931085medium

Abstract

Brain macrophage populations include parenchymal microglia, border-associated macrophages, and recruited monocyte-derived cells; together, they control brain development and homeostasis but are also implicated in aging pathogenesis and neurodegeneration. The phenotypes, localization, and functions o

Contradicts

DAM state may represent attempted repair — microglial ferroptosis could be an artifact of isolation protocols

Theranostics2023PMID:37351177medium

Contradicts

ACSL4-mediated lipid remodeling may serve neuroprotective functions in activated microglia

Redox Biol2023PMID:36581060medium

Abstract

ACSL4 role in ferroptotic lipid peroxidation and potential neuroprotective lipid remodeling pathways

Contradicts

Ferroptosis contributions relative to other cell death modalities in AD microglia remain unquantified

Cell Death Differ2025PMID:40271063medium

Abstract

Multiple cell death pathways including apoptosis necroptosis and pyroptosis in Alzheimer microglia

Contradicts

Microglial heterogeneity in AD is more complex than the binary DAM model suggests

verified_pubmedPMID:34292312medium

Abstract

Alzheimer's disease (AD) is characterized by extracellular aggregates of amyloid β peptides, intraneuronal tau aggregates, and neuronal death. This pathology triggers activation of microglia. Because variants of genes expressed in microglia correlate with AD risk, microglial response to pathology plausibly impacts disease course. In mouse AD models, single-cell RNA sequencing (scRNA-seq) analyses delineated this response as progressive conversion of homeostatic microglia into disease-associated

Contradicts

Antidiabetic medications affect dementia risk through multiple mechanisms, not just ferroptosis

verified_pubmedPMID:37869901medium

Abstract

The objective of this umbrella review and meta-analysis was to evaluate the effect of diabetes on risk of dementia, as well as the mitigating effect of antidiabetic treatments. We conducted a systematic umbrella review on diabetes and its treatment, and a meta-analysis focusing on treatment. We searched MEDLINE/PubMed, Embase, PsycINFO, CINAHL and the Cochrane Library for systematic reviews and meta-analyses assessing the risk of cognitive decline/dementia in individuals with diabetes until 2 Ju

Contradicts

Microglial cell death in AD may occur predominantly through neuroinflammation-driven mechanisms rather than ferroptosis specifically

Curr Opin Neurobiol2022PMID:35691251medium

Abstract

Despite the long-standing observation of vast neuronal loss in Alzheimer's disease (AD) our understanding of how and when neurons are eliminated is incomplete. While previous investigation has focused on apoptosis, several novel forms of cell death (i.e. necroptosis, parthanatos, ferroptosis, cuproptosis) have emerged that require further investigation. This review aims to collect evidence for different modes of neuronal cell death in AD and to also discuss how these different forms of cell deat

📖 Linked Papers (5)Export BibTeX ↗

Inflammatory Processes in Alzheimer's Disease-Pathomechanism, Diagnosis and Treatment: A Review.

Int J Mol Sci (2023) · PubMed:37047492 ↗

No figures

Pathogenesis of Alzheimer's Disease.

Int J Mol Sci (2022) · PubMed:36613544 ↗

No figures

Alzheimer's disease.

Handbook of clinical neurology (2019) · PubMed:31753135 ↗

No figures

Current understanding of Alzheimer's disease diagnosis and treatment.

F1000Research (2018) · PubMed:30135715 ↗

No figures

Alzheimer's disease.

European journal of neurology (2018) · PubMed:28872215 ↗

No figures

📙 Related Wiki Pages (1)

Composite Claim: Ferroptotic Priming Marconvergence_synthesis

🏥 Translation

🧬 3D Protein Structure — ACSL4

No curated PDB or AlphaFold mapping for ACSL4 yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for ACSL4 from GTEx v10.

💉 Clinical Trials (5)Relevance: 36%

0
Active

0
Completed

0
Total Enrolled

PHASE2
Highest Phase

Deferiprone for Iron Reduction in Alzheimer's DiseasePHASE2

COMPLETED·NCT03234686

Alzheimer Disease

Deferiprone

Effect of Selenium on Mild Cognitive ImpairmentPHASE2

COMPLETED·NCT03533257

Mild Cognitive Impairment

Selenomethionine

Pioglitazone in Alzheimer Disease (TOMORROW)PHASE3

COMPLETED·NCT00000145

Alzheimer Disease

Pioglitazone

N-Acetylcysteine for Neurodegeneration in PDPHASE2

COMPLETED·NCT03514875

Parkinson Disease Neurodegeneration

N-Acetylcysteine

Vitamin E and Selenium in Preventing ADPHASE2

RECRUITING·NCT05081219

Alzheimer Disease Prevention

Vitamin E Selenium

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for ACSL4 →

No DepMap CRISPR Chronos data found for ACSL4.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development

Cost

$0

Timeline

18 months

🏆 Tournament

🏆 Arenas / Elo

Elo Rating

1533 ±247

Record

1W / 1L / 0D

2 matches

Full Lineage ➔

📊 Market Indicators

7d Trend

↘

Falling

7d Momentum

▼ 3.9%

Volatility

Low

0.0072

Events (7d)

5

Price History

▼29.6%

💾 Resource Usage

LLM Tokens

21,110

$0.1267

Total Cost

$0.1267

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations

Prediction	Predicted	Observed	Status	Conf
Disease-associated oligodendrocytes isolated from AD brains will show significantly elevated ACSL4 protein expression and enriched PE-arachidonic acid species that positively correlate with proximity	ACSL4 protein levels in DAO cluster (OPALIN+/CNPASE+) will be ≥2-fold higher in AD cases (Braak III-VI, n≥20) vs. age-matched controls. Lipidomics will show ≥40	— no observation —	pending	0.78
Conditional knockout of Acsl4 in oligodendrocyte lineage cells will attenuate white matter degeneration and preserve cognitive function in 5xFAD mice at 12 months of age.	Acsl4-cKO 5xFAD mice will exhibit ≥30% reduction in corpus callosum demyelination (measured by MBP density immunohistochemistry) and ≥25% improvement in Morris	— no observation —	pending	0.72

🔮 Falsifiable Predictions (2)

pendingconf 78%

Disease-associated oligodendrocytes isolated from AD brains will show significantly elevated ACSL4 protein expression and enriched PE-arachidonic acid species that positively correlate with proximity to demyelinated white matter lesions.

Predicted outcome: ACSL4 protein levels in DAO cluster (OPALIN+/CNPASE+) will be ≥2-fold higher in AD cases (Braak III-VI, n≥20) vs. age-matched controls. Lipidomics wil

Falsification: ACSL4 protein levels show no difference or are downregulated in AD oligodendrocytes. PE-AA species are not elevated or show no correlation with white matter pathology. ACSL4+ oligodendrocytes are pref

pendingconf 72%

Conditional knockout of Acsl4 in oligodendrocyte lineage cells will attenuate white matter degeneration and preserve cognitive function in 5xFAD mice at 12 months of age.

Predicted outcome: Acsl4-cKO 5xFAD mice will exhibit ≥30% reduction in corpus callosum demyelination (measured by MBP density immunohistochemistry) and ≥25% improvement

Falsification: Acsl4-cKO mice show equivalent or worse white matter integrity and cognitive performance relative to 5xFAD controls; absence of detectable ACSL4 protein reduction in targeted cells (validation failure

📖 References (11)

ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition.
Doll S et al.. Nature chemical biology (2017)
PubMed↗DOI↗
A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease.
["Keren-Shaul H" et al.. Cell (2017)
PubMed↗DOI↗
Transcriptomic cytoarchitecture reveals principles of human neocortex organization
Jorstad NL et al.. Science (2023)
PubMed↗DOI↗
Patterns of Brain Iron Accumulation in Vascular Dementia and Alzheimer's Dementia Using Quantitative Susceptibility Mapping Imaging.
Moon Y et al.. Journal of Alzheimer's disease : JAD (2016)
PubMed↗DOI↗
Ablation of the Ferroptosis Inhibitor Glutathione Peroxidase 4 in Neurons Results in Rapid Motor Neuron Degeneration and Paralysis.
Chen L et al.. The Journal of biological chemistry (2015)
PubMed↗DOI↗
Human embryonic genome activation initiates at the one-cell stage.
Asami M et al.. Cell stem cell (2022)
PubMed↗DOI↗
Dual ontogeny of disease-associated microglia and disease inflammatory macrophages in aging and neurodegeneration.
Silvin A et al.. Immunity (2022)
PubMed↗DOI↗
High-intensity interval training ameliorates Alzheimer's disease-like pathology by regulating astrocyte phenotype-associated AQP4 polarization.
Feng S et al.. Theranostics (2023)
PubMed↗DOI↗
ACSL4 and the lipoxygenases 15/15B are pivotal for ferroptosis induced by iron and PUFA dyshomeostasis in dopaminergic neurons.
Bouchaoui H et al.. Free radical biology & medicine (2023)
PubMed↗DOI↗
Danggui Shaoyao San ameliorates Alzheimer's disease by regulating lipid metabolism and inhibiting neuronal ferroptosis through the AMPK/Sp1/ACSL4 signaling pathway.
Gong K et al.. Frontiers in pharmacology (2025)
PubMed↗DOI↗
Microglia in Alzheimer's disease at single-cell level. Are there common patterns in humans and mice?
Chen Y et al.. The Journal of experimental medicine (2021)
PubMed↗DOI↗

▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate

source	v1_phase_c_backfill
origin_type	gap_debate
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

5%

Debates

0

Incoming

1

Outgoing

0

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

Composite		78%
Mech.		73%
Evidence		82%
Novelty		54%
Feasibility		60%
Impact		—
Druggability		—
Safety		44%
Competition		—
Data avail.		—
Reproducibility		88%

📗 Cite This Artifact

ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlies White Matter Degeneration in Alzheimer's Disease

🧪 Overview

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — ACSL4

💉 Clinical Trials (5)Relevance: 36%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🔮 Predictions

📖 References (11)

🧬 Related Hypotheses — same target / disease (5)

💬 Discussion

📗 Cite This Artifact

ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlies White Matter Degeneration in Alzheimer's Disease

🧪 Overview

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — ACSL4

💉 Clinical Trials (5)Relevance: 36%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🧭 Related

activates (4)

amplifies (1)

associated with (14)

causes (14)

drives (1)

enhances (1)

implicated in (4)

investigated in (1)

participates in (1)

regulates (8)

therapeutic target for (1)

🔮 Predictions

📖 References (11)

🧬 Related Hypotheses — same target / disease (5)

💬 Discussion